Yang Xue, Zhu Chenfang, Gu Yan
Department of General Surgery, Shanghai Ninth Hospital affiliated with Shanghai Jiaotong University school of Medicine, Shanghai, 200011, China.
PLoS One. 2015 May 29;10(5):e0125655. doi: 10.1371/journal.pone.0125655. eCollection 2015.
An increasing number of patients with breast cancer are being offered immediate breast reconstruction (IBR). The aim of this study was to analyze the impact of IBR on the prognosis of patients with breast cancer.
We searched the electronic databases of Medline (Pubmed), ISI Web of Knowledge, Embase, and Google Scholar databases for studies reporting the overall recurrence, disease-free survival (DFS), and overall survival (OS) of patients after mastectomy only and mastectomy with IBR. With these data, we conducted a meta-analysis of the clinical outcomes.
Fourteen studies, including 3641 cases and 9462 controls, matched our criteria. Relevant information was extracted from these 14 studies. There was no significant heterogeneity (P for Q-statistic > 0.10 and I2 < 25%). Patients who underwent IBR showed no increased risk of overall recurrence of breast cancer (RR = 0.89; 95% confidence interval [CI]: 0.75, 1.04; P = 0.14). Furthermore, patients receiving IBR had similar DFS (RR = 1.04; 95%CI: 0.99, 1.08); P = 0.10) and OS (RR = 1.02; 95%CI: 0.99, 1.05; P = 0.24)) as those of control patients.
This meta-analysis provides evidence that IBR does not have an adverse effect on prognosis. These data suggest that IBR is an appropriate and safe choice for patients with breast cancer.
越来越多的乳腺癌患者接受即刻乳房重建(IBR)。本研究的目的是分析IBR对乳腺癌患者预后的影响。
我们检索了Medline(Pubmed)、ISI Web of Knowledge、Embase和谷歌学术数据库的电子数据库,以查找报告单纯乳房切除术后和乳房切除联合IBR术后患者的总复发率、无病生存率(DFS)和总生存率(OS)的研究。利用这些数据,我们对临床结果进行了荟萃分析。
14项研究符合我们的标准,包括3641例病例和9462例对照。从这14项研究中提取了相关信息。不存在显著异质性(Q统计量的P值>0.10且I2<25%)。接受IBR的患者乳腺癌总复发风险没有增加(RR = 0.89;95%置信区间[CI]:0.75,1.04;P = 0.14)。此外,接受IBR的患者的DFS(RR = 1.04;95%CI:0.99,1.08;P = 0.10)和OS(RR = 1.02;95%CI:0.99,1.05;P = 0.24)与对照患者相似。
这项荟萃分析提供了证据表明IBR对预后没有不利影响。这些数据表明IBR是乳腺癌患者的一种合适且安全的选择。